Page 11 - John Bluth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France News Provided By Share This Article For investors and media only RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) has granted an Autorisation Temporaire d'Utilisation de cohorte (cohort ATU), or Temporary Authorization for Use, for the use of berotralstat to prevent attacks of hereditary angioedema (HAE) in appropriate patients aged 12 and older. This cohort A...

Operator Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst fourth-quarter 2020 earnings call. [Operator instructions] Please be advised at today's conference is being recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, Mr. John Bluth, with BioCryst. You may begin. Senior Vice President, Investor Relations and Corporate Communications Thanks, Daphne. Good morning, and welcome to BioCryst's fourth-quarter 2020 corporate update and financial results conference call. Today's press release is available on our website. Par...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. BioCryst to Present at Upcoming Investor Conferences BioCryst Pharmaceuticals, Inc.February 18, 2021 GMT RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Cowen 41st Annual Healthcare Conference on Thursday, March 4, 2021 at 12:10 p.m. ET and the Barclays Annual Healthcare Conference on Thursday, March 11, 2021 at 8:00 a.m. ET. Both conferences are being held as virtual events. Links to a ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Share: RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO ™ (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. ORLADEYO is the first and only prophylactic HAE medication approved in Japan. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein...